Siemens Healthineers: The €400 Million Tariff Toll That's Dragging Down a €2.3 Billion Earnings Target

Siemens Healthineers shares near 52-week low as diagnostics division suffers from Chinese pricing reforms and US tariffs; buyback program and investor roadshows aim to stabilize stock.

The stock market has a way of ignoring even the loudest buy recommendations when the numbers don’t cooperate. Siemens Healthineers is living proof. The healthcare technology group has seen its shares shed nearly a quarter of their value since January, closing last Friday at €34.05 — a stone’s throw from the 52-week low of €32.84 set in May. Analysts see a path to recovery, with an average price target north of €49, but the market is betting against that optimism for now.

Two operational headwinds are largely responsible for the slide. The diagnostics division, which accounts for a significant slice of revenue, is being squeezed by Chinese pricing reforms and tepid demand. The spring-quarter sales drop in China pulled the entire group margin lower. On top of that, Siemens Healthineers is bracing for around €400 million in hit from US tariffs in fiscal 2026, with negative currency effects adding as much as €250 million. The combination has forced management to guide for adjusted earnings per share of €2.20 to €2.30 — the top end of which is only marginally below what analysts initially expected, but the uncertainty has already been priced into the stock.

Management isn’t standing still. Since June, the company has been running a share buyback programme worth up to €230 million, set to continue through January 2027. In the second week of June alone, Siemens Healthineers repurchased nearly 453,000 of its own shares — a clear attempt to put a floor under the stock. Meanwhile, the executive team has been hitting the road, holding investor meetings in London and Chicago, with stops planned in Dublin and Edinburgh later this month and into early July. The messaging centres on the "Elevating Health Globally" strategy, a push to rebuild trust with institutional shareholders.

The technical picture offers no relief. The relative strength index sits at 42.4, a neutral reading that signals no urgent buying pressure. The 200-day moving average is at €41.37, meaning the stock is trading almost 18% below that long-term trend line. Spontaneous buying interest is notably absent. Should the share price breach the €32.84 support, chart watchers warn of another wave of automated selling.

For the stock to stage a meaningful recovery, the diagnostics business in China needs to stabilise — and fast. The company’s imaging and Varian oncology units are performing solidly, but they can’t counterbalance the drag from the world’s second-largest economy on their own. Investors will be watching the third-quarter results due in July for any sign of improvement, and the February 2027 AGM, where a full spin-off of Siemens’ remaining stake in Healthineers will be decided, could prove a longer-term catalyst.

Right now, the buyback is the strongest argument against further erosion. Without a turnaround in China, it may be the only one.